Bilaketaren emaitzak - Sibylle Loibl

Findu emaitzak
  1. 1
    Optimal Systemic Treatment for Early Triple-Negative Breast Cancer

    Optimal Systemic Treatment for Early Triple-Negative Breast Cancer nork Jenny Furlanetto, Sibylle Loibl

    Argitaratua 2020
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Surgical treatment of primary breast cancer in the neoadjuvant setting

    Surgical treatment of primary breast cancer in the neoadjuvant setting nork Sherko Kümmel, Johannes Holtschmidt, Sibylle Loibl

    Argitaratua 2014
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial

    Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial nork Toralf Reimer, Äenne Glass, Edoardo Botteri, Sibylle Loibl, Oreste ­Gentilini

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Silencing of the HER2/neu Gene by siRNA Inhibits Proliferation and Induces Apoptosis in HER2/neu-Overexpressing Breast Cancer Cells

    Silencing of the HER2/neu Gene by siRNA Inhibits Proliferation and Induces Apoptosis in HER2/neu-Overexpressing Breast Cancer Cells nork Timo Faltus, Juping Yuan, Brigitte Zimmer, Andrea Krämer, Sibylle Loibl, Manfred Kaufmann, Klaus Strebhardt

    Argitaratua 2004
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition

    The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition nork Sherene Loi, Stefan Michiels, Sylvia Adams, Sibylle Loibl, Jan Budczies, Carsten Denkert, Roberto Salgado

    Argitaratua 2021
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Strategies for developing Ki67 as a useful biomarker in breast cancer

    Strategies for developing Ki67 as a useful biomarker in breast cancer nork Carsten Denkert, Jan Budczies, Gϋnter von Minckwitz, Stephan Wienert, Sibylle Loibl, Frederick Klauschen

    Argitaratua 2015
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study

    Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study nork Sibylle Loibl, Kathrin Schwedler, Gϋnter von Minckwitz, Renate Strohmeier, K. Mehta, M. Kaufmann

    Argitaratua 2007
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1–2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial

    Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1–2) in the Context of Breast Conserving Therapy: First Results Follow... nork Toralf Reimer, Angrit Stachs, Valentina Nekljudova, Sibylle Loibl, Steffi Hartmann, K. Wolter, Guido Hildebrandt, B. Gerber

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy

    PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Che... nork Sanxing Guo, Sibylle Loibl, Gϋnter von Minckwitz, Silvia Darb‐Esfahani, Bianca Lederer, Carsten Denkert

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer—a study by the AGO OVAR Germany

    Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer—a study by the AGO OVA... nork Felix Hilpert, Andreas du Bois, Elfriede Greimel, J. Hedderich, Geeske V. Krause, L Venhoff, Sibylle Loibl, Jacobus Pfisterer

    Argitaratua 2006
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

    A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies nork Andreas du Bois, Jens Huober, Peter Stopfer, J. Pfisterer, Pauline Wimberger, Sibylle Loibl, Volker L. Reichardt, Philipp Harter

    Argitaratua 2009
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy

    Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy nork Charlie Gourley, Judith Balmañà, Jonathan A. Ledermann, Violeta Serra, Rebecca Dent, Sibylle Loibl, Éric Pujade-Lauraine, Simon J. Boulton

    Argitaratua 2019
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis

    Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer-... nork Sibylle Loibl, Tomáš Skácel, Valentina Nekljudova, Hans Joachim Lück, Matthias Schwenkglenks, Thomas Brodowicz, Christoph Zielinski, Gϋnter von Minckwitz

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Classical pathology and mutational load of breast cancer – integration of two worlds

    Classical pathology and mutational load of breast cancer – integration of two worlds nork Jan Budczies, Michael Bockmayr, Carsten Denkert, Frederick Klauschen, Jochen K. Lennerz, Balázs Győrffy, Manfred Dietel, Sibylle Loibl, Wilko Weichert, Albrecht Stenzinger

    Argitaratua 2015
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    The definition of pregnancy-associated breast cancer is outdated and should no longer be used

    The definition of pregnancy-associated breast cancer is outdated and should no longer be used nork Frédéric Amant, Hanne Lefrère, Virginia F. Borges, Elyce Cardonick, Matteo Lambertini, Sibylle Loibl, Fedro A. Peccatori, Ann H. Partridge, Pepper Schedin

    Argitaratua 2021
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial

    Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial nork Jack Cuzick, Ivana Šestak, John Forbes, Mitch Dowsett, Simon Cawthorn, Robert E. Mansel, Sibylle Loibl, Bernardo Bonanni, D. Gareth Evans, Anthony Howell

    Argitaratua 2019
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences

    Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup s... nork Mark Kriegsmann, Volker Endris, Thomas Wolf, Nicole Pfarr, Albrecht Stenzinger, Sibylle Loibl, Carsten Denkert, Andreas Schneeweiß, Jan Budczies, Hans‐Peter Sinn, Wilko Weichert

    Argitaratua 2014
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy

    Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance sp... nork Sibylle Loibl, Gϋnter von Minckwitz, S. Weber, Hans‐Peter Sinn, Valérie B. Schini‐Kerth, Irina Lobysheva, Françoise Nepveu, G Wolf, Klaus Strebhardt, Manfred Kaufmann

    Argitaratua 2002
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial

    Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS... nork Jack Cuzick, Kim Chu, Brian Keevil, Adam R. Brentnall, Anthony Howell, Nicholas Zdenkowski, Bernardo Bonanni, Sibylle Loibl, Kaija Holli, D. Gareth Evans, Steve Cummings, Mitch Dowsett

    Argitaratua 2023
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial

    Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial nork G von Minckwitz, Sherko Kümmel, P. Vogel, Claus Hanusch, Holger Eidtmann, J. Hilfrich, B. Gerber, J. Huober, S. D. Costa, Christian Jackisch, Sibylle Loibl, K. Mehta, M. Kaufmann

    Argitaratua 2008
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: